ERYtech Pharma Enrolled Its Last Patient for Its Phase II GRASPALL Clinical Trial and Selects Philadelphia Science Center as US Headquarters

LYON,France & PHILADELPHIA, Pa.--(BUSINESS WIRE)--ERYtech Pharma announces the inclusion of its last patient in its Phase II clinical trial for relapsed Acute Lymphoblastic Leukaemia (ALL).